When the total daily drug dose was individualized to produce a steady-state serum salicylate concentration between 20 and 35 mg/dl, clinically acceptable fluctuations of serum concentrations occurred during both twice daily and three times daily administration. In 6 rheumatoid arthritis patients receiving choline magnesium trisalicylate, mean steady-state serum levels were the same, and the ranges of hourly mean concentrations during 8 and 12 hour dosage intervals were 19 to 27 mg/dl and 17 to 30 mg/dl, respectively. Changing the dosing interval from 8 to 12 hours required a 50% increase in the fractional doses, but resulted in an increase of only 3 mg/dl in mean peak concentration and a decrease of 1 mg/dl in mean minimum concentration.Salicylates are among the most effective antiinflammatory drugs used in the treatment of rheumatoid arthritis. At the serum concentrations recommended, salicylate serum half-life is prolonged (l,2). It is, therefore, theoretically possible to administer salicy- late at infrequent intervals in large fractions of the total daily dose.We studied two such regimens in which salicylate was administered at 8 and at 12 hour intervals to hospitalized patients with active rheumatoid arthritis. The hourly variation in steady-state salicylate concentration was measured. Choline magnesium trisalicylate (CMT) was used as the salicylate source since it may have fewer adverse effects on the gastrointestinal tract than aspirin, as judged by chromium-tagged red blood cell loss (3) and by endoscopic evaluation (4).
MATERIALS AND METHODSCholine magnesium trisalicylate was administered to 6 patients, 3 men and 3 women ranging in age from 24 to 57. All had active classic or definite rheumatoid arthritis (according to ARA criteria). None had clinically important renal, hepatic. or gastrointestinal disease as judged by history, physical examination, serum creatinine, urinalysis, SGOT. alkaline phosphatase. bilirubin. and LDH. Their characteristics are noted in Table I .During an initial outpatient phase of about 6 weeks. each patient's total daily dose of CMT was individualized by trial and error to achieve serum salicylate concentrations between 20 and 35 mg/dl at steady-state.After a minimum of 7 days on the selected dose, patients were hospitalized for 10 days at the Clinical Research Center, Center for Health Sciences, Los Angleles, California. The total daily dose was divided into three fractions and administered at 8 hour intervals for 5 days; the regimen was then changed so that two fractional doses were administered at I2 hour intervals for 5 days. The same total daily dose was used